Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011849 (
diabetes
)
277,896
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Diabetes
is caused by an absolute (type 1) or relative (type 2) deficiency of insulin-producing beta cells. We have disrupted expression of the mitochondrial protein
frataxin
selectively in pancreatic beta cells. Mice were born healthy but subsequently developed impaired glucose tolerance progressing to overt
diabetes mellitus
. These observations were explained by impairment of insulin secretion due to a loss of beta cell mass in knockout animals. This phenotype was preceded by elevated levels of reactive oxygen species in knockout islets, an increased frequency of apoptosis, and a decreased number of proliferating beta cells. Hence, disruption of the
frataxin
gene in pancreatic beta cells causes
diabetes
following cellular growth arrest and apoptosis, paralleled by an increase in reactive oxygen species in islets. These observations might provide insight into the deterioration of beta cell function observed in different subtypes of
diabetes
in humans.
...
PMID:Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass. 1292 93
Iron is essential for oxidation-reduction catalysis and bioenergetics; however, unless appropriately shielded, this metal plays a crucial role in the formation of toxic oxygen radicals that can attack all biological molecules. Organisms are equipped with specific proteins designed for iron acquisition, export and transport, and storage, as well as with sophisticated mechanisms that maintain the intracellular labile iron pool at an appropriate level. Despite these homeostatic mechanisms, organisms often face the threat of either iron deficiency or iron overload. This review describes several hereditary iron-overloading conditions that are confined to the brain. Recently, a mutation in the L-subunit of ferritin has been described that causes the formation of aberrant L-ferritin with an altered C-terminus. Individuals with this mutation in one allele of L-ferritin have abnormal aggregates of ferritin and iron in the brain, primarily in the globus pallidus. Patients with this dominantly inherited late-onset disease present with symptoms of extrapyramidal dysfunction. Mice with a targeted disruption of a gene for iron regulatory protein 2 (IRP2), a translational repressor of ferritin, misregulate iron metabolism in the intestinal mucosa and the central nervous system. Significant amounts of ferritin and iron accumulate in white matter tracts and nuclei, and adult IRP2-deficient mice develop a movement disorder consisting of ataxia, bradykinesia, and tremor. Mutations in the
frataxin
gene are responsible for Friedreich's ataxia, the most common of the inherited ataxias. Frataxin appears to regulate mitochondrial iron-sulfur cluster formation, and the neurologic and cardiac manifestations of Friedreich's ataxia are due to iron-mediated mitochondrial toxicity. Patients with Hallervorden-Spatz syndrome, an autosomal recessive, progressive neurodegenerative disorder, have mutations in a novel pantothenate kinase gene (PANK2). The cardinal feature of this extrapyramidal disease is pathologic iron accumulation in the globus pallidus. The defect in PANK2 is predicted to cause the accumulation of cysteine, which binds iron and causes oxidative stress in the iron-rich globus pallidus. Finally, aceruloplasminemia is an autosomal recessive disorder of iron metabolism caused by loss-of-function mutations in ceruloplasmin gene that leads to misregulation of both systemic and central nervous system iron trafficking. Affected individuals suffer from extrapyramidal signs, cerebellar ataxia, progressive neurodegeneration of retina, and
diabetes mellitus
. Excessive iron depositions are found in the brain, liver, pancreas, and other parenchymal cells, but plasma iron concentrations are decreased. These conditions are not common, but awareness about them is important for differential diagnosis of various neurodegenerative disorders.
...
PMID:Hereditary causes of disturbed iron homeostasis in the central nervous system. 1510 72
More than 20 syndromes among the significant and increasing number of degenerative diseases of neuronal tissues are known to be associated with
diabetes mellitus
, increased insulin resistance and obesity, disturbed insulin sensitivity, and excessive or impaired insulin secretion. This review briefly presents such syndromes, including Alzheimer disease, ataxia-telangiectasia, Down syndrome/trisomy 21,
Friedreich ataxia
, Huntington disease, several disorders of mitochondria, myotonic dystrophy, Parkinson disease, Prader-Willi syndrome, Werner syndrome, Wolfram syndrome, mitochondrial disorders affecting oxidative phosphorylation, and vitamin B(1) deficiency/inherited thiamine-responsive megaloblastic anemia syndrome as well as their respective relationship to malignancies, cancer, and aging and the nature of their inheritance (including triplet repeat expansions), genetic loci, and corresponding functional biochemistry. Discussed in further detail are disturbances of glucose metabolism including impaired glucose tolerance and both insulin-dependent and non-insulin-dependent
diabetes
caused by neurodegeneration in humans and mice, sometimes accompanied by degeneration of pancreatic beta-cells. Concordant mouse models obtained by targeted disruption (knock-out), knock-in, or transgenic overexpression of the respective transgene are also described. Preliminary conclusions suggest that many of the diabetogenic neurodegenerative disorders are related to alterations in oxidative phosphorylation (OXPHOS) and mitochondrial nutrient metabolism, which coincide with aberrant protein precipitation in the majority of affected individuals.
...
PMID:Neurodegenerative disorders associated with diabetes mellitus. 1517 61
A GAA-repeat in the
X25
gene is causing Friedreich's ataxia (FRDA), a common neurodegenerative disease and >20% of FRDA patients develop type II
diabetes
(T2D). Linkage has previously been detected between T2D and chromosome 9p13-q21, the region that harbours the
X25
gene, but association studies of this gene in T2D have been contradicting. Here, we examined whether genetic variation in the
X25
gene is associated with risk for T2D. The GAA-repeat and 18 single nucleotide polymorphisms (SNPs) covering the
X25
gene were genotyped in 220 trios in which the affected offspring had abnormal glucose tolerance. Any nominally significant findings were examined in an independent sample consisting of 523 individuals with T2D and 326 healthy controls. Previously reported results were analysed together with our data using a meta-analysis approach. There was no association between the GAA-repeat and T2D susceptibility in our study, which was supported by the meta-analysis including all previous publications. One SNP (rs2498429), 8.2 kb downstream of
X25
, was nominally associated with T2D in the trios (P=0.02) and showed a trend of association in the same direction in the case-controls (P=0.08; combined permuted P=0.01). Further analysis showed that the nine-marker haplotype containing the rare allele of rs2498429 was nominally associated with T2D in the trios (P<0.01) as well as in the case-controls (P=0.03). In conclusions, this study excludes a role of genetic variation within the
X25
gene, but instead suggests that genetic variation downstream the
X25
gene, may increase risk for T2D.
...
PMID:Haplotype construction of the FRDA gene and evaluation of its role in type II diabetes. 1582 63
Friedreich ataxia
is a severe autosomal-recessive disease characterized by neurodegeneration, cardiomyopathy and
diabetes
, resulting from reduced synthesis of the mitochondrial protein
frataxin
. Although
frataxin
is ubiquitously expressed,
frataxin
deficiency leads to a selective loss of dorsal root ganglia neurons, cardiomyocytes and pancreatic beta cells. How
frataxin
normally promotes survival of these particular cells is the subject of intense debate. The predominant view is that
frataxin
sustains mitochondrial energy production and other cellular functions by providing iron for heme synthesis and iron-sulfur cluster (ISC) assembly and repair. We have proposed that
frataxin
not only promotes the biogenesis of iron-containing enzymes, but also detoxifies surplus iron thereby affording a critical anti-oxidant mechanism. These two functions have been difficult to tease apart, however, and the physiologic role of iron detoxification by
frataxin
has not yet been demonstrated in vivo. Here, we describe mutations that specifically impair the ferroxidation or mineralization activity of yeast
frataxin
, which are necessary for iron detoxification but do not affect the iron chaperone function of the protein. These mutations increase the sensitivity of yeast cells to oxidative stress, shortening chronological life span and precluding survival in the absence of the anti-oxidant enzyme superoxide dismutase. Thus, the role of
frataxin
is not limited to promoting ISC assembly or heme synthesis. Iron detoxification is another function of
frataxin
relevant to anti-oxidant defense and cell longevity that could play a critical role in the metabolically demanding environment of non-dividing neuronal, cardiac and pancreatic beta cells.
...
PMID:Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. 1637 22
Excessive body iron or iron overload occurs under conditions such as primary (hereditary) hemochromatosis and secondary iron overload (hemosiderosis), which are reaching epidemic levels worldwide. Primary hemochromatosis is the most common genetic disorder with an allele frequency greater than 10% in individuals of European ancestry, while hemosiderosis is less common but associated with a much higher morbidity and mortality. Iron overload leads to iron deposition in many tissues especially the liver, brain, heart and endocrine tissues. Elevated cardiac iron leads to diastolic dysfunction, arrhythmias and dilated cardiomyopathy, and is the primary determinant of survival in patients with secondary iron overload as well as a leading cause of morbidity and mortality in primary hemochromatosis patients. In addition, iron-induced cardiac injury plays a role in acute iron toxicosis (iron poisoning), myocardial ischemia-reperfusion injury,
Friedreich ataxia
and neurodegenerative diseases. Patients with iron overload also routinely suffer from a range of endocrinopathies, including
diabetes mellitus
and anterior pituitary dysfunction. Despite clear connections between elevated iron and clinical disease, iron transport remains poorly understood. While low-capacity divalent metal and transferrin-bound transporters are critical under normal physiological conditions, L-type Ca2+ channels (LTCC) are high-capacity pathways of ferrous iron (Fe2+) uptake into cardiomyocytes especially under iron overload conditions. Fe2+ uptake through L-type Ca2+ channels may also be crucial in other excitable cells such as pancreatic beta cells, anterior pituitary cells and neurons. Consequently, LTCC blockers represent a potential new therapy to reduce the toxic effects of excess iron.
...
PMID:Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. 1660 32
Frataxin is a mitochondrial protein involved in iron metabolism. Defective expression of
frataxin
causes
Friedreich ataxia
(FA), an inherited degenerative syndrome characterized by ataxia, cardiomyopathy, and high incidence of
diabetes
. Here we report that
frataxin
-deficient cells are more prone to undergo stress-induced mitochondrial damage and apoptosis, while the overexpression of
frataxin
confers protection to a variety of cell types. Moreover, we reveal the existence of an extramitochondrial pool of
frataxin
, which can efficiently prevent mitochondrial damage and apoptosis in different cellular systems. Remarkably, extramitochondrial
frataxin
can fully replace mitochondrial
frataxin
in promoting survival of FA cells.
...
PMID:A pool of extramitochondrial frataxin that promotes cell survival. 1660 49
Friedreich's ataxia (FA) is one of the genetic syndromes sometimes associated with
diabetes
and the most common hereditary ataxia. It is a autosomal recessive neurodegenerative disease, caused by a mutation in the FRDA gene, which originates decreased expression of
frataxin
, a mitochondrial protein involved in iron metabolism. The disorder is usually manifest in childhood and is characterised by ataxia, dysarthria, scoliosis and feet deformity. About two thirds of patients have hypertrophic cardiomyopathy, 10% have
diabetes
and 20% have another glucose homeostasis disorder. Both insulin resistance and beta-cell dysfunction are implicated in this patients'
diabetes
pathophysiology. The mean half-life is 35 years. Cause of death is usually related to cardiomyopathy or
diabetes
' complications. We report the case study of two twin sisters with 28 years old, in whom FA was diagnosed in the first decade, both of them with
diabetes
since their early twenties. A third sister with FA is reported, with no glucose homeostasis disorder. They also have two healthy male brothers. Based in this cases, the FA associated
diabetes
pathophysiology is discussed, concerning the therapeutic approach to these patients and to their diabetic relatives without neurologic symptoms. The role of molecular genetic testing and genetic counselling are also debated.
...
PMID:[Friedreich ataxia and diabetes mellitus--family study]. 1668 89
Published evidence suggests that adiposity in humans may be linked to impaired energy expenditure for reasons widely unresolved. We have generated mice with a systemic impairment of oxidative phosphorylation (OXPHOS) due to aP2 cre-mediated targeted disruption, and unexpectedly ubiquitous reduction of mitochondrial
frataxin
protein expression. Only when maintained on a high-calorie diet resembling Westernized eating habits, these animals accumulate additional body fat, leading to increased body mass, and develop
diabetes mellitus
, despite the fact that both calorie uptake and physical activity were identical to that in control animals. This phenotype is caused by a mild but significant reduction in total energy expenditure paralleled by increased expression of ATP citrate lyase, a rate-limiting step in de novo synthesis of fatty acids and triglycerides. Taken together, these findings indicate that a limited impairment in oxidative metabolism within the mitochondria directly predisposes mammals to excessive body weight gain.
...
PMID:Reduced expression of mitochondrial frataxin in mice exacerbates diet-induced obesity. 1740 27
This review concerns the development of small molecule therapeutics for the inherited neurodegenerative disease
Friedreich ataxia
(
FRDA
).
FRDA
is caused by transcriptional repression of the nuclear
FXN
gene, encoding the essential mitochondrial protein
frataxin
and accompanying loss of
frataxin
protein. Frataxin insufficiency leads to mitochrondrial dysfunction and progressive neurodegeneration, along with scoliosis,
diabetes
and cardiomyopathy. Individuals with
FRDA
generally die in early adulthood from the associated heart disease, the most common cause of death in
FRDA
. While antioxidants and iron chelators have shown promise in ameliorating the symptoms of the disease, there is no effective therapy for
FRDA
that addresses the cause of the disease, the loss of
frataxin
protein. Gene therapy and protein replacement strategies for
FRDA
are promising approaches; however, current technology is not sufficiently advanced to envisage treatments for
FRDA
coming from these approaches in the near future. Since the
FXN
mutation in
FRDA
, expanded GAA.TTC triplets in an intron, does not alter the amino acid sequence of
frataxin
protein, gene reactivation would be of therapeutic benefit. Thus, a number of laboratories have focused on small molecule activators of
FXN
gene expression as potential therapeutics, and this review summarizes the current status of these efforts, as well as the molecular basis for gene silencing in
FRDA
.
...
PMID:Small molecules affecting transcription in Friedreich ataxia. 1782 40
<< Previous
1
2
3
4
5
6
7
8
Next >>